Table 3. Disease progression among anti-hypertensive drugs.
ACEI/ARB: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers; CCB: calcium channel blocker; BB: beta blocker; CI: confidence interval.
| Comorbid | Mortality
rate(%) |
Days of death
(mean) |
RR | 95%CI |
|---|---|---|---|---|
| Geriatri (age>60 years old) | 19,35 | 23,52 | ||
| DM | 15,79 | 27,91 | ||
| HT | 17,95 | 25,98 | ||
| Heart Disease | 25,00 | 22 | ||
| Chronic Kidney Disease | 0,00 | 0 | ||
| AntiHypertensive Drugs | ||||
| Single | ||||
| ACEI/ARB | 7,14 | 23 | 0,33 | (0,05-2,49) |
| CCB | 4,55 | 28,79 | 0,16 | (0,02-1,22) |
| BB | 54,55 | 21,11 | 9,82 | (2,33-41,89) * |
| Double | ||||
| ACEI/ARB+CCB | 15,38 | 20,39 | 0,85 | (0,14-5,06) |
| ACEI/ARB+BB | 14,29 | 14 | 0,81 | (0,10-6,51) |
| CCB+BB | 25 | 15,67 | 1,27 | (0,17-9,72) |
| Overall | ||||
| Single | 17,02 | 25,19 | 1,28 | (0,42-3,49) |
| Double | 16,67 | 19,81 | 1,10 | (0,37-3,31) |
| Triple | 0 | 0 | ||
| Severity of Chest X-Ray | ||||
| Normal | 0 | 0 | ||
| Mild | 7,14 | 19 | ||
| Moderate | 14,29 | 18 | ||
| Severe and Critcal ill | 24,32 | 25,03 | ||
| Inflammatory marker | ||||
| Leucocyte | ||||
| >6.16x10 3/uL | 12,99 | 26,22 | ||
| <6,16x10 3/uL | 2,60 | 21,27 | ||
| Neutrophil-lymphocyte ratio (NLR) | ||||
| High (>6.5) | 7,79 | 25,88 | ||
| Low (<6,5) | 7,79 | 24 | ||
| Absolute Lymphocyte Count (ALC) | ||||
| Low < 1.0 × 10 3 cells/µL | 7,79 | 23,54 | ||
| High > 1.0x10 3 cells/µL | 7,79 | 27,31 | ||
| CRP | ||||
| High (>41,8 mg/L) | 6,49 | 23,26 | ||
| Low (<41,8 mg/L) | 9,09 | 27,64 | ||
| Procalcitonin | ||||
| High (>0,07 ng/mL) | 9,09 | 23,96 | ||
| Low (<0,07 ng/mL) | 6,49 | 28,07 |
DM, diabetes mellitus; HT, hypertension; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta blocker; CCB, calcium channel blocker; ICU, intensive Care Unit; SD, standard deviation; NLR, Neutrophil-lymphocyte ratio; ALC, Absolute Lymphocyte Count; CRP, C- Reactive Protein; * : marked significantly according 95% confidence interval.